em·tri·cit·a·bine

(ĕm′trĭ-sĭt′ə-bēn′, -sī′tə-)

An antiviral drug, C₈H₁₀FN₃O₃S, that is a nucleoside reverse transcriptor inhibitor and is used in combination with other drugs to treat HIV infection or to reduce the risk of HIV infection.

[emtri- (probably Em(ory) University, where the drug was discovered + Tri(angle) Pharmaceuticals, company to which it was licensed) + -citabine, nucleoside analog antiviral and anticancer drug suff.; see zalcitabine.]

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

Translations

emtricitabine

n emtricitabina

Mentioned in

Truvada

References in periodicals archive

The tenofovir alafenamide-based therapies include Genvoya (elvitegravir 150mg/cobicistat 15 mg/ emtricitabine 200mg/tenofovir alafenamide 10mg), Descovy (emtricitabine 200mg/tenofovir alafenamide 10mg and 25mg) tablets and Odefsey (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) tablets.

Ontario Drug Benefit Program to offer eligible HIV patients access to Gilead Sciences Canada's Biktarvy tablets

Descovy, made up of emtricitabine and tenofovir alafenamide, is a proposed indicator of pre-exposure prophylaxis in men and transgender women at high risk to HIV infection.

US FDA Gives Thumbs Up To Gilead Sciences' HIV Indicator

In addition, because emtricitabine, the other active pharmaceutical ingredient of Truvada, faces generic competition in the European Union, Truvada also faces generic competition in the European Union and certain other countries outside of the United States.

Gilead says generic HIV prevention drug coming in 2020

said that the FDA has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)--in combination with safer sex practices--to reduce the risk of sexually acquired HIV-1 in at-risk adolescents.

TVuvada to reduce risk of HIV-1

The combination of dolutegravir plus fixed-dose tenofovir disoproxil fumarate and emtricitabine is administered as 2 pills per day.

HIV update: which single-tablet regimens, and when

The overall rate of resistance to emtricitabine or tenofovir--the antiretrovirals contained in fixed-dose combination in Truvada, the only Food and Drug Administration-approved agent for HIV PrEP--was 5 cases in 9,222 trial participants, for a risk of 0.05%.

With HIV PrEP, benefits outweigh resistance risk

Gilead Sciences has received approval from the FDA for Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) single tablet regimen for the treatment of HIV-1 infection.

FDA approves Gilead's second TAF-Based STR: Merck's ZEPATIER approved for HCV

Participants were randomly assigned to one of five regimens: 300 mg oral tenofovir and a placebo; oral tenofovir-emtricitabine (300 mg tenofovir and 200 mg emtricitabine) and a placebo; two placebos; vaginal 1% tenofovir gel; or vaginal placebo gel.

Poor user adherence may explain lack of efficacy in HIV prophylaxis trial

The daily regimen containing emtricitabine, tenofovir disoproxil fumarate, and rilpivirine HCl is virologically and immunologically effective, well-tolerated, and safe with benefits in the lipid profile in the majority of patients (Figure 1) [2].

Simultaneous spectrophotometric method for determination of emtricitabine and tenofovir disoproxil fumarate in three-component tablet formulation containing rilpivirine hydrochloride

Emtricitabine (5-fluoro-1-(2R, 5S)-[2-(hydroxymethyl)-1,3oxathiolan-5-yl]cytosine) (Figure 1(a)) is a potent deoxycytidine nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus (HIV) infection [1,2].

Optimization (central composite design) and validation of HPLC method for investigation of emtricitabine loaded poly(lactic-co-glycolic acid) nanoparticles: in vitro drug release and in vivo pharmacokinetic studies